 | Up a level |
Werner, Raphael Sven; Curioni-Fontecedro, Alessandra; Mauti, Laetitia A; Addeo, Alfredo; Peters, Solange; Frauenfelder, Thomas; Puhan, Milo A; Haberecker, Martina; Bubendorf, Lukas; Finazzi, Tobias; Guckenberger, Matthias; Cafarotti, Stefano; Geiser, Thomas; Opitz, Isabelle (2024). Lung Cancer in Switzerland. Journal of thoracic oncology, 19(3), pp. 385-394. Elsevier 10.1016/j.jtho.2023.12.005
Furrer, Katarzyna; Weder, Walter; Eboulet, Eric Innocents; Betticher, Daniel; Pless, Miklos; Stupp, Roger; Krueger, Thorsten; Perentes, Jean Yannis; Schmid, Ralph A; Lardinois, Didier; Furrer, Markus; Früh, Martin; Peters, Solange; Curioni-Fontecedro, Alessandra; Stahel, Rolf A; Rothschild, Sacha I; Hayoz, Stefanie; Opitz, Isabelle (2022). Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment. The journal of thoracic and cardiovascular surgery, 164(6), 1587-1602.e5. Elsevier 10.1016/j.jtcvs.2022.03.034
Akhoundova, Dilara; Haberecker, Martina; Fritsch, Ralph; Höller, Sylvia; Kiessling, Michael K; Rechsteiner, Markus; Rüschoff, Jan H; Curioni-Fontecedro, Alessandra (2022). Targeting ALK in Neuroendocrine Tumors of the Lung. Frontiers in oncology, 12, p. 911294. Frontiers Research Foundation 10.3389/fonc.2022.911294
Hiltbrunner, Stefanie; Spohn, Meta-Lina; Wechsler, Ramona; Akhoundova, Dilara; Bankel, Lorenz; Kasser, Sabrina; Bihr, Svenja; Britschgi, Christian; Maathuis, Marloes H; Curioni-Fontecedro, Alessandra (2022). Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. Cancers, 14(1) MDPI AG 10.3390/cancers14010075
Peters, Solange; Danson, Sarah; Hasan, Baktiar; Dafni, Urania; Reinmuth, Niels; Majem, Margarita; Tournoy, Kurt G; Mark, Michael T; Pless, Miklos; Cobo, Manuel; Rodriguez-Abreu, Delvys; Falchero, Lionel; Moran, Teresa; Ortega Granados, Ana Laura; Monnet, Isabelle; Mohorcic, Katja; Sureda, Bartomeu Massutí; Betticher, Daniel; Demedts, Ingel; Macias, Jose Antionio; ... (2020). A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. Journal of thoracic oncology, 15(10), pp. 1647-1656. Elsevier 10.1016/j.jtho.2020.06.011
Peters, Solange; Stahel, Rolf A; Dafni, Urania; Aix, Santiago Ponce; Massutí, Bartomeu; Gautschi, Oliver; Coate, Linda; López Martín, Ana; van Heemst, Robbert; Berghmans, Thierry; Meldgaard, Peter; Cobo Dols, Manuel; Noguera, Javier Garde; Curioni-Fontecedro, Alessandra; Rauch, Daniel; Mark, Michael T; Cuffe, Sinead; Biesma, Bonne; van Henten, Arjen Mj; Vidal, Óscar Juan; ... (2017). Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first line platinum-based doublet chemotherapy stratified by Veristrat good versus Veristrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial. Journal of thoracic oncology, 12(4), pp. 752-762. Elsevier 10.1016/j.jtho.2016.12.017
